FDA Approves Cancer Drug That Doubles Eligible Patients

Men diagnosed with advanced prostate cancer now have access to a targeted treatment much earlier in their fight, potentially changing the course of their disease before it progresses.

The FDA approved Pluvicto, a radioligand therapy, for patients with metastatic hormone-sensitive prostate cancer. This approval nearly doubles the number of men who can receive this precision treatment, extending its use beyond late-stage disease to patients at their initial metastatic diagnosis.

The approval came after a clinical trial showed promising results. Patients receiving Pluvicto combined with standard hormone therapy reduced their risk of disease progression or death by 33% compared to standard treatment alone.

More than 186,000 men worldwide are diagnosed with this stage of prostate cancer each year. Despite existing treatments, about half of these patients see their disease progress to a more resistant form within 20 months, making earlier intervention crucial.

Pluvicto works by combining a targeting molecule with radioactive particles that bind specifically to prostate cancer cells expressing a protein called PSMA. Once attached, the treatment delivers radiation directly to cancer cells, minimizing damage to healthy tissue. The biomarker is present in more than 80% of prostate cancer patients.

Dr. Michael Morris from Memorial Sloan Kettering Cancer Center noted that having this radioligand therapy available at an earlier stage meaningfully expands options for physicians and represents real progress for patients. The treatment maintained patients' quality of life throughout the trial, an important consideration when treating any cancer.

The Ripple Effect

This approval signals a broader shift in cancer care toward precision medicine and earlier intervention. Gina Carithers, CEO of the Prostate Cancer Foundation, called it a milestone that ensures men have a targeted option from day one of their metastatic diagnosis.

The manufacturer has built five production sites across the US to meet growing demand, delivering treatment to facilities within five days of ordering. This infrastructure investment reflects confidence that radioligand therapy will become a fundamental pillar of oncology care, potentially inspiring similar approaches for other cancers.

For men facing a prostate cancer diagnosis and their families, this approval means access to more personalized treatment options when they need them most.